Indivior Pharmaceuticals, Inc. (INDV) FY2026 YTD Q3 P&L / Income Statement
Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)
Revenue by Business Segment by Geography
Swipe to see the full flow
Chart details
Indivior Pharmaceuticals, Inc. (INDV) FY2026 YTD Q3 P&L / Income Statement
Income statement for 2026-01-01 through 2026-09-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Net revenue
- 1,016,000,000 US dollars
- Cost of sales
- 140,000,000 US dollars
- Gross profit
- 875,000,000 US dollars
- Total operating expenses
- 398,000,000 US dollars
- Operating income
- 477,000,000 US dollars
- Other income (expense), net (calculated)
- negative 20,000,000 US dollars
- Income before income taxes
- 457,000,000 US dollars
- Income tax expense (benefit)
- 109,000,000 US dollars
- Net income
- 348,000,000 US dollars
- Reportable Segment - UNITED STATES
- 880,000,000 US dollars
- Reportable Segment - Rest of World
- 136,000,000 US dollars
- Selling, general and administrative
- 364,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
- Research and development
- 33,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- The amounts that make up gross profit come to $876.00 M and gross profit is $875.00 M; the $1.00 M difference is within the rounding of the filed amounts.

Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!
